Published online Sep 27, 2021. doi: 10.4240/wjgs.v13.i9.1079
Peer-review started: January 26, 2021
First decision: March 29, 2021
Revised: April 3, 2021
Accepted: June 16, 2021
Article in press: June 16, 2021
Published online: September 27, 2021
Processing time: 234 Days and 23.8 Hours
Hepatic resection (HR) results in an inflammatory response that can be modified by perioperative steroid administration. However, it remains to be determined if this response's attenuation translates to a reduction in complications.
Stress from major surgery results in an inflammatory response secondary to cytokine and free radical release. This inflammatory response is essential for healing and restoration of physiologic function; however, it can increase morbidity, mortality, and worsen postoperative outcomes if excessive. Modifying the inflammatory response by perioperative steroid administration could improve surgical outcomes. Besides, inflammatory markers are increasingly shown to predict short-term perioperative and long-term oncologic outcomes following HR. Thus, modulation of inflammatory response to improve surgical outcomes remains an unmet need in hepatic surgery.
To evaluate if perioperative administration of steroids reduces complications following HR.
A systematic review of randomized controlled trials (RCTs) was conducted on PubMed, Embase, and Cochrane Central Register of Controlled Trials to evaluate the effect of perioperative steroid (compared to placebo or no intervention) use in patients undergoing HR. Clinical outcomes were extracted, and meta-analysis was performed.
Eight RCTs including 590 patients were included. Perioperative steroid administration was associated with significant reduction in postoperative complications [odds ratios: 0.58; 95% confidence intervals (CI): (0.35, 0.97), P = 0.04]. There was also improvement in biochemical and inflammatory markers, including serum bilirubin on postoperative day 1 [MD: -0.27; 95%CI: (-0.47, -0.06), P = 0.01], C-reactive protein on postoperative day 3 [MD: -4.89; 95%CI: (-5.83, -3.95), P < 0.001], and IL-6 on postoperative day 1 [MD: -54.84; 95%CI: (-63.91, -45.76), P < 0.001].
Perioperative steroids administration in HR may reduce overall complications, postoperative bilirubin, and inflammation. Further studies are needed to determine the optimal dose and duration, and patient selection.
The International Study Group on Liver Surgery needs to make recommendations to standardize the perioperative use of steroids in patients undergoing HR liver resection as type, dose, and time of administration of perioperative steroids could impact clinical outcomes. Lastly, there was also a lack of long-term follow-up data, and thus, the impact on survival outcomes is not established.